ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO950

Outcomes of Kidney Transplant Recipients in Singapore With COVID-19 Infection With Delta and Omicron Variants

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • D'Costa, Matthew, National University Hospital, Singapore, Singapore, Singapore
  • Sran, Hersharan Kaur, National University Hospital, Singapore, Singapore, Singapore
  • Wong, Emmett Tsz Yeung, National University Hospital, Singapore, Singapore, Singapore
  • Vathsala, Anantharaman, National University Hospital, Singapore, Singapore, Singapore
Background

Kidney transplant recipients (KTR) are at higher risk for breakthrough COVID-19 infections and progression to severe disease. Herein, we compare the outcomes of KTR infected with the Delta and Omicron variants.

Methods

We performed a retrospective, single-centre study of all SARS-CoV-2-infected KTR confirmed by PCR from 17/09/21 to 30/04/22. At diagnosis, anti-metabolite doses were halved with further reductions of immunosuppression with increasing disease severity. Treatment for KTR not requiring supplemental oxygen (SuppO2) on admission was guided by SARS-CoV-2 spike antibody (SpAb), Roche® Cobas SARS-CoV-2-S assay. Sotrovimab 500mg IV was given if SpAb<100 U/mL. With community emergence of Omicron subvariant BA.2, sotrovimab was replaced by tixagevimab/cilgavimab (EVUSHELD™) 600mg IM in KTR with SpAb<250 U/mL or remdesivir if SpAb>250 U/mL. KTR with SuppO2 were treated with dexamethasone +/- remdesivir and immunomodulator therapy (baricitinib or tocilizumab). Characteristics and outcomes between KTR with Delta and Omicron were compared.

Results

Clinical characteristics and outcomes are summarized in Table 1. Baseline demographics were similar between groups. Vaccination rates increased over time in concert with government vaccine programs and communications by our team. KTR with Omicron had higher vaccination rates, higher likelihood of SpAb>250 U/mL, and were less likely to have AKI, SuppO2, ICU stay, and mortality (p<0.05 for all). Of 16 KTR with Omicron with SuppO2, 5 were unvaccinated and only 1/16 had SpAb>250 u/mL.

Conclusion

Severe disease was less frequent in KTR with Omicron likely due to improved vaccination rates, higher SpAb, and virus characteristics. However, KTR remain at risk for severe disease especially if unvaccinated or if SpAb is low.